Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts

P. Ferdinándy, Matyas Koltai, A. Tósaki, Philippe Berthet, Thierry Tarrade, André Esanu, Pierre Braquet

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The effect of cicletanine, a novel furopyridine antihypertensive drug was compared with that of nitren-dipine, a dihydropyridine slow calcium channel blocker, on cardiac function and reperfusion-induced ventricular arrhythmias in isolated working rat hearts subjected to 10-min ischemia induced by ligation of the left main coronary artery followed by 10-min reperfusion. Before ischemia, cicletanine and nitrendipine, perfused at concentrations of 3 ± 10-5, 6 ± 10-5, 10-4, and 2 ± 10-4or 10-8M, respectively, did not influence heart rate (HR), LV developed pressure (LVDP), its first derivative (LVdP/dtmax) and LV end-diastolic pressure (LVEDP), whereas aortic flow (AF) was decreased by 2 ± 10-4M cicletanine only. Coronary flow (CF) remained unchanged by various cicletanine concentrations but was slightly increased by nitrendipine. In the concentration range of 3 ± 10-5-10-4M, cicletanine improved AF either in ischemia or during reperfusion, whereas 2 ± 10-4M had no such effect. Nitrendipine slightly attenuated ischemia/reperfusion-induced decrease in AF. Cicletanine and nitrendipine enhanced LVDP during ischemia. Ischemia-induced deterioration of LVdP/dtmaxwas reduced by cicletanine, during reperfusion, but this parameter was reduced by nitrendipine and the highest cicletanine concentration. Cicletanine decreased LVEDP significantly during ischemia and reperfusion, but nitrendipine had no such effect. All cicletanine concentrations reduced the incidence of irreversible ventricular fibrillation (VF) during reperfusion, an effect roughly concentration dependent in the range of 3 ± 10-5-10-4M, whereas nitrendipine had no influence on arrhythmias.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalJournal of Cardiovascular Pharmacology
Volume19
Issue number2
Publication statusPublished - 1992

Fingerprint

Nitrendipine
Reperfusion
Ischemia
Cardiac Arrhythmias
cicletanine
Blood Pressure
Pressure
Calcium Channel Blockers
Ventricular Fibrillation
Antihypertensive Agents
Ligation
Coronary Vessels
Heart Rate
Incidence

Keywords

  • Arrhythmias
  • Cardiac function
  • Cicletanine
  • Coronary occlusion
  • Ischemia
  • Nitrendipine
  • Rat heart
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts. / Ferdinándy, P.; Koltai, Matyas; Tósaki, A.; Berthet, Philippe; Tarrade, Thierry; Esanu, André; Braquet, Pierre.

In: Journal of Cardiovascular Pharmacology, Vol. 19, No. 2, 1992, p. 181-189.

Research output: Contribution to journalArticle

Ferdinándy, P. ; Koltai, Matyas ; Tósaki, A. ; Berthet, Philippe ; Tarrade, Thierry ; Esanu, André ; Braquet, Pierre. / Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts. In: Journal of Cardiovascular Pharmacology. 1992 ; Vol. 19, No. 2. pp. 181-189.
@article{7f236f2b0637484a8c34fdee3d3640ba,
title = "Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts",
abstract = "The effect of cicletanine, a novel furopyridine antihypertensive drug was compared with that of nitren-dipine, a dihydropyridine slow calcium channel blocker, on cardiac function and reperfusion-induced ventricular arrhythmias in isolated working rat hearts subjected to 10-min ischemia induced by ligation of the left main coronary artery followed by 10-min reperfusion. Before ischemia, cicletanine and nitrendipine, perfused at concentrations of 3 ± 10-5, 6 ± 10-5, 10-4, and 2 ± 10-4or 10-8M, respectively, did not influence heart rate (HR), LV developed pressure (LVDP), its first derivative (LVdP/dtmax) and LV end-diastolic pressure (LVEDP), whereas aortic flow (AF) was decreased by 2 ± 10-4M cicletanine only. Coronary flow (CF) remained unchanged by various cicletanine concentrations but was slightly increased by nitrendipine. In the concentration range of 3 ± 10-5-10-4M, cicletanine improved AF either in ischemia or during reperfusion, whereas 2 ± 10-4M had no such effect. Nitrendipine slightly attenuated ischemia/reperfusion-induced decrease in AF. Cicletanine and nitrendipine enhanced LVDP during ischemia. Ischemia-induced deterioration of LVdP/dtmaxwas reduced by cicletanine, during reperfusion, but this parameter was reduced by nitrendipine and the highest cicletanine concentration. Cicletanine decreased LVEDP significantly during ischemia and reperfusion, but nitrendipine had no such effect. All cicletanine concentrations reduced the incidence of irreversible ventricular fibrillation (VF) during reperfusion, an effect roughly concentration dependent in the range of 3 ± 10-5-10-4M, whereas nitrendipine had no influence on arrhythmias.",
keywords = "Arrhythmias, Cardiac function, Cicletanine, Coronary occlusion, Ischemia, Nitrendipine, Rat heart, Reperfusion",
author = "P. Ferdin{\'a}ndy and Matyas Koltai and A. T{\'o}saki and Philippe Berthet and Thierry Tarrade and Andr{\'e} Esanu and Pierre Braquet",
year = "1992",
language = "English",
volume = "19",
pages = "181--189",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Cicletanine improves myocardial function deteriorated by ischemia/reperfusion in isolated working rat hearts

AU - Ferdinándy, P.

AU - Koltai, Matyas

AU - Tósaki, A.

AU - Berthet, Philippe

AU - Tarrade, Thierry

AU - Esanu, André

AU - Braquet, Pierre

PY - 1992

Y1 - 1992

N2 - The effect of cicletanine, a novel furopyridine antihypertensive drug was compared with that of nitren-dipine, a dihydropyridine slow calcium channel blocker, on cardiac function and reperfusion-induced ventricular arrhythmias in isolated working rat hearts subjected to 10-min ischemia induced by ligation of the left main coronary artery followed by 10-min reperfusion. Before ischemia, cicletanine and nitrendipine, perfused at concentrations of 3 ± 10-5, 6 ± 10-5, 10-4, and 2 ± 10-4or 10-8M, respectively, did not influence heart rate (HR), LV developed pressure (LVDP), its first derivative (LVdP/dtmax) and LV end-diastolic pressure (LVEDP), whereas aortic flow (AF) was decreased by 2 ± 10-4M cicletanine only. Coronary flow (CF) remained unchanged by various cicletanine concentrations but was slightly increased by nitrendipine. In the concentration range of 3 ± 10-5-10-4M, cicletanine improved AF either in ischemia or during reperfusion, whereas 2 ± 10-4M had no such effect. Nitrendipine slightly attenuated ischemia/reperfusion-induced decrease in AF. Cicletanine and nitrendipine enhanced LVDP during ischemia. Ischemia-induced deterioration of LVdP/dtmaxwas reduced by cicletanine, during reperfusion, but this parameter was reduced by nitrendipine and the highest cicletanine concentration. Cicletanine decreased LVEDP significantly during ischemia and reperfusion, but nitrendipine had no such effect. All cicletanine concentrations reduced the incidence of irreversible ventricular fibrillation (VF) during reperfusion, an effect roughly concentration dependent in the range of 3 ± 10-5-10-4M, whereas nitrendipine had no influence on arrhythmias.

AB - The effect of cicletanine, a novel furopyridine antihypertensive drug was compared with that of nitren-dipine, a dihydropyridine slow calcium channel blocker, on cardiac function and reperfusion-induced ventricular arrhythmias in isolated working rat hearts subjected to 10-min ischemia induced by ligation of the left main coronary artery followed by 10-min reperfusion. Before ischemia, cicletanine and nitrendipine, perfused at concentrations of 3 ± 10-5, 6 ± 10-5, 10-4, and 2 ± 10-4or 10-8M, respectively, did not influence heart rate (HR), LV developed pressure (LVDP), its first derivative (LVdP/dtmax) and LV end-diastolic pressure (LVEDP), whereas aortic flow (AF) was decreased by 2 ± 10-4M cicletanine only. Coronary flow (CF) remained unchanged by various cicletanine concentrations but was slightly increased by nitrendipine. In the concentration range of 3 ± 10-5-10-4M, cicletanine improved AF either in ischemia or during reperfusion, whereas 2 ± 10-4M had no such effect. Nitrendipine slightly attenuated ischemia/reperfusion-induced decrease in AF. Cicletanine and nitrendipine enhanced LVDP during ischemia. Ischemia-induced deterioration of LVdP/dtmaxwas reduced by cicletanine, during reperfusion, but this parameter was reduced by nitrendipine and the highest cicletanine concentration. Cicletanine decreased LVEDP significantly during ischemia and reperfusion, but nitrendipine had no such effect. All cicletanine concentrations reduced the incidence of irreversible ventricular fibrillation (VF) during reperfusion, an effect roughly concentration dependent in the range of 3 ± 10-5-10-4M, whereas nitrendipine had no influence on arrhythmias.

KW - Arrhythmias

KW - Cardiac function

KW - Cicletanine

KW - Coronary occlusion

KW - Ischemia

KW - Nitrendipine

KW - Rat heart

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=0026558902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026558902&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 181

EP - 189

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -